Top

Published in:

01-06-2005 | Poster Presentation

Hereditary breast cancer – a spectrum of pathogenic mutations and unknown variants of BRCA1 and BRCA2 genes in the Czech Republic: efficiency of testing and clinical follow-up

Authors: L Foretova, M Lukesova, P Vasickova, M Navratilova, H Pavlu, J Kuklova, V Urbankova, D Hanouskova, B Dvorackova, E Machackova

Published in: Breast Cancer Research | Special Issue 2/2005

Excerpt

Germline mutations in the highly penetrant cancer susceptibility genes BRCA1 and BRCA2 cause genetic predisposition to breast and ovarian cancers. Molecular genetic testing of pathogenic mutations in these two genes is an effective method for breast cancer risk prediction. Genetic counselling and testing has been provided to high-risk women in our institute since 1997. Until now 589 probands (580 women and nine men) with breast/ovarian cancer have been tested for BRCA1/2 germline mutations. …

Machackova E, Damborsky J, Valik D, Foretova L: Novel germline BRCA1 and BRCA2 mutations in breast/ovarian cancer families from the Czech Republic. Hum Mutat. 2001, 18: 545-10.1002/humu.1232.CrossRefPubMed

Foretova L, Machackova E, Navratilova M, Pavlu H, Hruba M, Lukesova M, Valik D: BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat. 2004, 23: 397-398. 10.1002/humu.9226.CrossRefPubMed

Title: Hereditary breast cancer – a spectrum of pathogenic mutations and unknown variants of BRCA1 and BRCA2 genes in the Czech Republic: efficiency of testing and clinical follow-up
Authors: L Foretova
M Lukesova
P Vasickova
M Navratilova
H Pavlu
J Kuklova
V Urbankova
D Hanouskova
B Dvorackova
E Machackova
Publication date: 01-06-2005
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1093

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 2/2005

The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling

Discovering genetic profiles by array-CGH in familial breast tumors

Identification of differentially expressed genes in canine mammary tumor cell lines using a newly developed canine-specific cDNA microarray

Proteomic approaches to early detection of breast cancer

Identification of novel sequence alterations and the functional analysis of the BRCA1 promoter/5'-UTR in families from Upper Silesia, Poland

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer